Catalog_No	Drug Name/ Product Name	CAS	Product Line	Target	Path	Area	Citation
HY-78921	Fmoc-3VVD-OH	863971-44-2	ADC Related	ADC Linker	Antibody-drug Conjugate/ADC Related	Cancer	[A1]
HY-78931	Boc-Dap-NE	160800-65-7	ADC Related	ADC Linker	Antibody-drug Conjugate/ADC Related	Cancer
HY-13631E	Deruxtecan	1599440-13-7	ADC Related	Drug-Linker Conjugates for ADC	Antibody-drug Conjugate/ADC Related	Cancer	[C1] [C2]
HY-78738	MC-Val-Cit-PAB	159857-80-4	ADC Related	ADC Linker	Antibody-drug Conjugate/ADC Related	Cancer	[D1]
HY-15575	VcMMAE	646502-53-6	ADC Related	Drug-Linker Conjugates for ADC; Microtubule/Tubulin	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton	Cancer	[E1] [E2] [E3]
HY-15162	Monomethyl auristatin E	474645-27-7	ADC Related	ADC Cytotoxin; Apoptosis; Microtubule/Tubulin	Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton	Cancer	[F1] [F2]
HY-128952	Tesirine	1595275-62-9	ADC Related	DNA Alkylator/Crosslinker; Drug-Linker Conjugates for ADC	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage	Cancer	[G1] [G2]
HY-13631D	Dxd	1599440-33-1	ADC Related	ADC Cytotoxin; Topoisomerase	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage	Cancer	[H1]
HY-138298	Trastuzumab deruxtecan (solution)	1826843-81-5	ADC Related	Antibody-Drug Conjugates (ADCs); EGFR	Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK	Cancer	[I1] [I2] [I3] [I4]
HY-138298A	Trastuzumab deruxtecan	1826843-81-5	ADC Related	Antibody-Drug Conjugates (ADCs); EGFR	Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK	Cancer	[J1] [J2] [J3] [J4]

---

[A1]. Michinori Akaiwa, et al. Synthesis and Evaluation of Linear and Macrocyclic Dolastatin 10 Analogues Containing Pyrrolidine Ring Modifications. ACS Omega. 2018 May 31;3(5):5212-5221.

---

[C1]. NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1.
[C2]. Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.

---

[D1]. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders.

---

[E1]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897.
[E2]. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87.
[E3]. Jianmin Fang, et al. Anti-her2 antibody and conjugate thereof. US 20160304621 A1.

---

[F1]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897.
[F2]. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87.

---

[G1]. Tiberghien AC, et al. Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload. ACS Med Chem Lett. 2016;7(11):983-987. Published 2016 May 24.
[G2]. Hartley JA, et al. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Sci Rep. 2018;8(1):10479. Published 2018 Jul 11.

---

[H1]. Ogitani Y, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016 Oct 15;22(20):5097-5108.

---

[I1]. Kumagai K, et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020 Dec;111(12):4636-4645.
[I2]. Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518.
[I3]. Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.
[I4]. Iwata TN, et, al. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. PLoS One. 2019 Oct 1;14(10):e0222280.

---

[J1]. Kumagai K, et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020 Dec;111(12):4636-4645.
[J2]. Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518.
[J3]. Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.
[J4]. Iwata TN, et, al. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. PLoS One. 2019 Oct 1;14(10):e0222280.